Annual CFO
-$570.57 M
-$181.77 M-46.75%
31 December 2022
Summary:
Mirati Therapeutics annual cash flow from operations is currently -$570.57 million, with the most recent change of -$181.77 million (-46.75%) on 31 December 2022. During the last 3 years, it has fallen by -$181.77 million (-46.75%).MRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$143.71 M
-$12.31 M-9.37%
30 September 2023
Summary:
Mirati Therapeutics quarterly cash flow from operations is currently -$143.71 million, with the most recent change of -$12.31 million (-9.37%) on 30 September 2023.MRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$594.10 M
-$5.90 M-1.00%
30 September 2023
Summary:
Mirati Therapeutics TTM cash flow from operations is currently -$594.10 million, with the most recent change of -$5.90 million (-1.00%) on 30 September 2023.MRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -46.8% | -4.2% | -52.8% |
| 5 y5 years | -286.2% | -243.0% | -302.2% |
MRTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -5061.6% | -1021.0% | -5266.2% |
Mirati Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$143.71 M(+9.4%) | -$594.10 M(+1.0%) |
| June 2023 | - | -$131.40 M(-30.9%) | -$588.19 M(-2.0%) |
| Mar 2023 | - | -$190.18 M(+47.7%) | -$600.28 M(+5.2%) |
| Dec 2022 | -$570.57 M(+46.8%) | -$128.80 M(-6.5%) | -$570.57 M(-1.6%) |
| Sept 2022 | - | -$137.81 M(-4.0%) | -$579.75 M(+18.6%) |
| June 2022 | - | -$143.49 M(-10.6%) | -$488.98 M(+11.4%) |
| Mar 2022 | - | -$160.47 M(+16.3%) | -$438.85 M(+12.9%) |
| Dec 2021 | -$388.80 M(+43.2%) | -$137.99 M(+193.4%) | -$388.80 M(+18.8%) |
| Sept 2021 | - | -$47.03 M(-49.6%) | -$327.24 M(-8.3%) |
| June 2021 | - | -$93.37 M(-15.4%) | -$356.97 M(+10.5%) |
| Mar 2021 | - | -$110.42 M(+44.5%) | -$322.94 M(+18.9%) |
| Dec 2020 | -$271.53 M(+83.8%) | -$76.42 M(-0.4%) | -$271.53 M(+14.6%) |
| Sept 2020 | - | -$76.76 M(+29.4%) | -$237.01 M(+22.7%) |
| June 2020 | - | -$59.34 M(+0.6%) | -$193.12 M(+12.1%) |
| Mar 2020 | - | -$59.00 M(+40.8%) | -$172.25 M(+16.6%) |
| Dec 2019 | -$147.73 M(+110.7%) | -$41.90 M(+27.5%) | -$147.73 M(+16.7%) |
| Sept 2019 | - | -$32.87 M(-14.5%) | -$126.62 M(+11.2%) |
| June 2019 | - | -$38.47 M(+11.6%) | -$113.92 M(+17.9%) |
| Mar 2019 | - | -$34.48 M(+65.8%) | -$96.63 M(+37.9%) |
| Dec 2018 | -$70.10 M(+8.3%) | -$20.80 M(+3.1%) | -$70.10 M(+11.1%) |
| Sept 2018 | - | -$20.17 M(-4.8%) | -$63.07 M(+8.8%) |
| June 2018 | - | -$21.18 M(+166.5%) | -$57.99 M(+6.5%) |
| Mar 2018 | - | -$7.95 M(-42.3%) | -$54.42 M(-15.9%) |
| Dec 2017 | -$64.71 M(-4.9%) | -$13.77 M(-8.8%) | -$64.71 M(-3.5%) |
| Sept 2017 | - | -$15.09 M(-14.3%) | -$67.06 M(-4.6%) |
| June 2017 | - | -$17.62 M(-3.4%) | -$70.27 M(+1.4%) |
| Mar 2017 | - | -$18.23 M(+13.1%) | -$69.30 M(+1.9%) |
| Dec 2016 | -$68.02 M(+34.1%) | -$16.12 M(-11.9%) | -$68.02 M(+0.1%) |
| Sept 2016 | - | -$18.30 M(+9.9%) | -$67.92 M(+3.7%) |
| June 2016 | - | -$16.64 M(-1.8%) | -$65.50 M(+13.1%) |
| Mar 2016 | - | -$16.95 M(+5.8%) | -$57.89 M(+14.2%) |
| Dec 2015 | -$50.71 M(+54.9%) | -$16.03 M(+1.0%) | -$50.71 M(+17.2%) |
| Sept 2015 | - | -$15.87 M(+75.6%) | -$43.27 M(+16.9%) |
| June 2015 | - | -$9.04 M(-7.5%) | -$37.02 M(+9.8%) |
| Mar 2015 | - | -$9.78 M(+13.8%) | -$33.73 M(+3.0%) |
| Dec 2014 | -$32.75 M | -$8.59 M(-10.7%) | -$32.75 M(+2.7%) |
| Sept 2014 | - | -$9.62 M(+67.4%) | -$31.87 M(+16.1%) |
| June 2014 | - | -$5.75 M(-34.7%) | -$27.45 M(-11.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$8.80 M(+14.1%) | -$30.91 M(+4.9%) |
| Dec 2013 | -$29.45 M(+76.9%) | -$7.71 M(+48.5%) | -$29.45 M(+9.4%) |
| Sept 2013 | - | -$5.20 M(-43.6%) | -$26.93 M(+3.9%) |
| June 2013 | - | -$9.21 M(+25.4%) | -$25.92 M(+32.7%) |
| Mar 2013 | - | -$7.34 M(+41.5%) | -$19.53 M(+17.3%) |
| Dec 2012 | -$16.65 M(+47.0%) | -$5.19 M(+24.0%) | -$16.65 M(+10.3%) |
| Sept 2012 | - | -$4.18 M(+48.4%) | -$15.09 M(+13.6%) |
| June 2012 | - | -$2.82 M(-36.8%) | -$13.28 M(+3.9%) |
| Mar 2012 | - | -$4.46 M(+22.9%) | -$12.78 M(+12.9%) |
| Dec 2011 | -$11.32 M(-28.0%) | -$3.63 M(+53.0%) | -$11.32 M(+11.6%) |
| Sept 2011 | - | -$2.37 M(+2.5%) | -$10.15 M(-15.9%) |
| June 2011 | - | -$2.32 M(-22.9%) | -$12.07 M(-3.9%) |
| Mar 2011 | - | -$3.00 M(+22.5%) | -$12.57 M(-20.1%) |
| Dec 2010 | -$15.73 M(-23.1%) | -$2.45 M(-42.9%) | -$15.73 M(-4.2%) |
| Sept 2010 | - | -$4.30 M(+52.9%) | -$16.42 M(-12.5%) |
| June 2010 | - | -$2.81 M(-54.4%) | -$18.76 M(-11.9%) |
| Mar 2010 | - | -$6.17 M(+95.9%) | -$21.30 M(+4.1%) |
| Dec 2009 | -$20.46 M(+11.1%) | -$3.15 M(-52.6%) | -$20.46 M(+8.2%) |
| Sept 2009 | - | -$6.64 M(+24.0%) | -$18.91 M(+11.1%) |
| June 2009 | - | -$5.35 M(+0.5%) | -$17.03 M(-4.1%) |
| Mar 2009 | - | -$5.32 M(+233.0%) | -$17.76 M(-3.6%) |
| Dec 2008 | -$18.41 M(-18.1%) | -$1.60 M(-66.4%) | -$18.41 M(-22.5%) |
| Sept 2008 | - | -$4.75 M(-21.8%) | -$23.76 M(+5.1%) |
| June 2008 | - | -$6.08 M(+1.7%) | -$22.61 M(-4.2%) |
| Mar 2008 | - | -$5.98 M(-13.9%) | -$23.60 M(+5.0%) |
| Dec 2007 | -$22.49 M(-295.6%) | -$6.95 M(+93.0%) | -$22.49 M(+27.7%) |
| Sept 2007 | - | -$3.60 M(-49.2%) | -$17.61 M(+47.8%) |
| June 2007 | - | -$7.08 M(+45.5%) | -$11.92 M(+32.8%) |
| Mar 2007 | - | -$4.87 M(+135.5%) | -$8.97 M(-178.0%) |
| Dec 2006 | $11.50 M(-202.3%) | -$2.07 M(-198.6%) | $11.50 M(+3.9%) |
| Sept 2006 | - | $2.09 M(-150.7%) | $11.07 M(+93.5%) |
| June 2006 | - | -$4.13 M(-126.5%) | $5.72 M(-13.8%) |
| Mar 2006 | - | $15.60 M(-725.5%) | $6.63 M(-159.0%) |
| Dec 2005 | -$11.24 M(+85.4%) | -$2.49 M(-23.4%) | -$11.24 M(+28.5%) |
| Sept 2005 | - | -$3.26 M(+1.1%) | -$8.75 M(+59.3%) |
| June 2005 | - | -$3.22 M(+41.8%) | -$5.49 M(+141.8%) |
| Mar 2005 | - | -$2.27 M | -$2.27 M |
| Dec 2004 | -$6.07 M(-505.2%) | - | - |
| Dec 2003 | $1.50 M | - | - |
FAQ
- What is Mirati Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Mirati Therapeutics?
- What is Mirati Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Mirati Therapeutics?
What is Mirati Therapeutics annual cash flow from operations?
The current annual CFO of MRTX is -$570.57 M
What is the all time high annual CFO for Mirati Therapeutics?
Mirati Therapeutics all-time high annual cash flow from operations is $11.50 M
What is Mirati Therapeutics quarterly cash flow from operations?
The current quarterly CFO of MRTX is -$143.71 M
What is the all time high quarterly CFO for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly cash flow from operations is $15.60 M
What is Mirati Therapeutics TTM cash flow from operations?
The current TTM CFO of MRTX is -$594.10 M
What is the all time high TTM CFO for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM cash flow from operations is $11.50 M